Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00525668
  4. Details
NCT00525668 Clinical Trial

Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

Relapsing-remitting Multiple Sclerosis Clinical Trial

— SuniMS  

Official title:
Sunphenon EGCg (Epigallocatechin-gallate) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00525668
Other study ID # 2006-006323-39
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 2007
Est. completion date November 2012

Study information
Verified date July 2021
Source Charite University, Berlin, Germany
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypothesis: Sunphenon, a green tea extract containing 95% egcg, given daily as oral medication over a period of 18 months has anti-inflammatory and neuroprotective properties in patients with relapsing-remitting multiple sclerosis as assessed by magnetic resonance imaging and clinical examination (EDSS and MSFC).

Description:

This multicentric, national study investigates the efficacy and safety of EGCG in patients with relapsing-remitting multiple sclerosis.

Recruitment information / eligibility
Status Completed
Enrollment 120
Est. completion date November 2012
Est. primary completion date November 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - male and female subjects age 18 to 60 - relapsing-remitting course of MS - stable treatment with glatiramer acetate at least 6 months prior to inclusion Exclusion Criteria: - primary or secondary progressive forms of MS - clinically relevant heart, lung, liver, kidney diseases - regular hepatotoxic co-medication - drug addiction - alcohol abuse

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• epigallocatechin-gallate (Sunphenon)
200 mg twice daily, after 3 months 400 mg twice daily
• placebo
2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily

Locations
Country Name City State
Germany NeuroCure Clinical Research Center, Charite University, Berlin Berlin
Germany Outpatient Clinic for Neuroimmunology at the ECRC, Charite University, Berlin Berlin

Sponsors (1)
Lead Sponsor Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary number of new T2 lesions on brain MRI performed after 18 months of Sunphenon treatment compared to baseline MRI in the verum arm versus placebo 18 months
Secondary development of brain atrophy under treatment with EGCG vs. placebo 18 months
Secondary Safety and tolerability 18 months
See also
  Status Clinical Trial Phase
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Terminated NCT02222948 - Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis Phase 2
Completed NCT02293967 - Mass Balance Study of MT-1303 Phase 1
Terminated NCT01790269 - Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod
Terminated NCT01701856 - Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Phase 4
Terminated NCT00398528 - An fMRI Study of Treatment Optimization Comparing Two Disease Modifying Therapies Used to Treat Relapsing Remitting Multiple Sclerosis Phase 4
Completed NCT00315367 - A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties Phase 4
Terminated NCT04032171 - Study of Evobrutinib in Participants With RMS Phase 3
Completed NCT01930708 - A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes Phase 4
Completed NCT03000647 - Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis N/A
Completed NCT02205489 - Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA Phase 4
Completed NCT02753088 - Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis Phase 3
Recruiting NCT01466114 - Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition Phase 2
Completed NCT01244139 - Safety Study of BIIB033 in Subjects With Multiple Sclerosis Phase 1
Completed NCT01416155 - Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis Phase 2
Completed NCT00559702 - Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Phase 1
Completed NCT00493116 - Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta Phase 4
Completed NCT01943526 - Ireland Natalizumab (TYSABRI) Observational Program
Terminated NCT02342704 - Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants Phase 4
Completed NCT02310048 - Comparative Oral Bioavailability Study of MT-1303 Phase 1

External Links